Pulmonary-Allergy panel to consider Firazyr
Executive Summary
Jerini's subcutaneous injectable treatment for hereditary angioedema Firazyr (icatibant) is slated for a Feb. 20 review by FDA's Pulmonary-Allergy Advisory Committee. The bradykinin blocker is under priority review, with a user fee deadline in late April or early May...
Jerini's subcutaneous injectable treatment for hereditary angioedema Firazyr (icatibant) is slated for a Feb. 20 review by FDA's Pulmonary-Allergy Advisory Committee. The bradykinin blocker is under priority review, with a user fee deadline in late April or early May.... |